Market Place
Sourcing Support
Blincyto Improves Survival In Pediatric B-ALL With Chemotherapy
07 Dec 2024 //
PR NEWSWIRE
Amgen nabs new Blincyto approval for certain type of leukemia
17 Jun 2024 //
ENDPTS
Amgen Biologic Blinatumomab Receives Suppl Approval in US
14 Jun 2024 //
FDA
FDA Approves BLINCYTO For CD19-Positive Ph-Negative B-ALL
14 Jun 2024 //
PR NEWSWIRE
Amgen`s Biologic Blincyto (blinatumomab) Receives Approval in the U.S.
08 Feb 2024 //
FDA
FDA Grants Full Approval For Blincyto® To Treat Minimal Residual
21 Jun 2023 //
PR NEWSWIRE
Amgen`s Biologic Blincyto (Blinatumomab) Receives Approval in the U.S.
20 Jun 2023 //
FDA
WuXi inks $1.5B GSK pact, a big biobuck bet but a blip in billions lost US list
06 Jan 2023 //
ENDPTS
ASH: Amgen`s Blincyto looks to establish new leukemia standard
13 Dec 2022 //
FIERCEPHARMA
Blincyto Added To Consolidation Chemotherapy Improves Survival With B-All
13 Dec 2022 //
PRNEWSWIRE
Amgen`s Biologic BLINCYTO (Blinatumomab) Receives Approval in the U.S.
05 Dec 2022 //
FDA
Amgen`s Biologic Blincyto (Blinatumomab) Receives Approval in the U.S.
18 Feb 2022 //
FDA
Amgen reports positive data from BLINCYTO study in leukaemia patients
03 Mar 2021 //
CLINICALTRIALSARENA
BLINCYTO® (Blinatumomab) Demonstrated Significantly Prolonged Event-Free
02 Mar 2021 //
PRNEWSWIRE
BeiGene Announces the Approval in China of BLINCYTO® (Blinatumomab)
07 Dec 2020 //
BUSINESSWIRE
Amgen`s Blincyto (Blinatumomab) Receives Supplemental Approval In US
24 Mar 2020 //
FDA
Amgen Commences Strategic Collaboration With BeiGene to Expand Oncology in China
03 Jan 2020 //
PRESS RELEASE
Amgen teams up with BeiGene in cancer a $2.7B stake
01 Nov 2019 //
ENDPTS
The top 10 most-expensive meds in the U.S.—and they`re not the usual suspects
13 Jun 2019 //
FIERCE PHARMA
Amgen’s Blincyto (Blinatumomab ) Receives Supplemental Approval In US
24 Apr 2019 //
FDA
NICE evidence request for Blincyto for acute lymphoblastic leukaemia
06 Mar 2019 //
PHARMA TIMES
Copyright © 2024 LePro PharmaCompass OPC Private Limited, All rights reserved.